Trial

No. of Patients

Age Group (years)

Induction Chemotherapy

Outcomes

Induction Mortality

Trend of a benefit for GO in favorable-risk AML

Author, year

Total

No GO v GO

CR Rate

Survival

Study name

No GO v GO

No GO v GO

No GO v GO

Petersdorf et al.2009

627

229 v 277

18 - 60

DNR 45 mg/m² per day on days 1 - 3 + Ara-C 100 mg/m² per day on days 1 - 7 + GO 6 mg/m² on day 4 v DNR 60 mg/m² per day on days 1 - 3 + Ara-C 100 mg/m² per day on days 1 - 7

69% v 66%^*

RFS^* (data not available)

0.8% v 5.8%                            (p = 0.002)

NA

SWOG 0106

EFS, NA

median OS35 M v 31 M^*

Burnett et al.2011

1113

557 v 556

<60

DA v ADE v FLAG-IDA ± GO 3 mg/m² on day 1

83% v 82%^*

5-year RFS35% v 39%^*

6% v 7%^*

Yes

MRC AML15

EFS, NA

5-year OS41% v 43%^*

Castaigne et al.2012

278

139 v 139

50 - 70

DNR 60 mg/m² per day on days 1 - 3 + Ara-C 200 mg/m² per days 1 - 7 ± GO 3 mg/m² per day on days 1, 4, 7

75% v 81%^*

2-year RFS23% v 50%

(p = 0.0003)

4% v 6.5%^*

Yes

ALFA-0701

2-year EFS17% v 41%

(p = 0.0003)

2-year OS42% v 53%

(p = 0.037)

Burnett et al.2012

1115

556 v 559

51 - 84

DNR 50 mg/m² per day on days 1, 3, 5 and CLO 20 mg/m² per day on days 1 - 5 or Ara-C 100 mg/m² every 12 hours on days 1 - 10 ± GO 3 mg/m² on day 1

58% v 62%^*

3-year RFS16% v 21%

(p = 0.04)

11% v 12%^*

Yes

AML16

EFS, NA

3-year OS20% v 25%

(p = 0.05)

Brunnberg et al.2012

119

58 v 57

60 - 83

Ara-C 100 mg/m² per day on days 1-7 + DNR 60 mg/m² per day on days 1-3 v Ara-C 100 mg/m² per day on days 1-7 + GO 6 mg/m² on day 1 and 4 mg/m² on day 8

55% v 54%^*

median RFS8 M v 14 M^*

5% v 19%

(p = 0.021)

NA

EFS, NA

OS, 9 M v 10 M^*